A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer.
CONCLUSIONS: The combination of ixabepilone and cetuximab was active and had acceptable toxicity. The efficacy results are similar to single-agent ixabepilone and gemcitabine-based combination therapies in patients with advanced pancreatic cancer. Exploratory analyses suggest a trend toward improved survival for patients who experienced rash.
PMID: 23112883 [PubMed]
Source: Gastrointestinal Cancer Research - Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Erbitux | Gastroenterology | Hematology | Pancreas | Pancreatic Cancer | Study | Toxicology